Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study: Sehhoon Park, Yurimi Lee, Jiyun Lee, Yang Won Min, Hong Kwan Kim, Joon Young Choi, Hyun Ae Jung, Yong Soo Choi, Yoon-La Choi, Young Mog Shim, Jong-Mu Sun; Cancer Res Treat. 2024;56(2):567-579. Published online October 16, 2023; DOI: https://doi.org/10.4143/crt.2023.897

Abstract PDF Supplementary Material PubReader ePub: Purpose
Programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in metastatic esophageal squamous cell carcinoma (ESCC) therapy. However, data is still limited regarding neoadjuvant immunotherapy for operable ESCC.
Materials and Methods
Patients with clinical stage T2 or T3 and N0 ESCC received three cycles of nivolumab therapy every two weeks before surgical resection. The primary endpoint is major pathologic responses (MPR) rate (≤ 10% of residual viable tumor [RVT]).
Results
Total 20 patients completed the planned nivolumab therapy. Among them, 17 patients underwent surgery as protocol, showing MPR in two patients (MPR rate, 11.8%), including one pathologic complete response, on conventional pathologic response evaluation. Pathologic response was re-evaluated using the immune-related pathologic response criteria based on immune-related RVT (irRVT). Three patients were classified as immunologic major pathologic response (iMPR; ≤ 10% irRVT, iMPR rate: 17.6%), five as pathologic partial response (> 10% and < 90% irRVT), and nine as pathologic nonresponse (≥ 90% irRVT). The combined positive score (CPS) for PD-L1 in the baseline samples was predictable for iMPR, with the probability as 37.5% in CPS ≥ 10 (3/8) and 0% in CPS < 10 (0/9).
Conclusion
Although the efficacy of neoadjuvant nivolumab therapy was modest in unselected ESCC patients, further researches on neoadjuvant immunotherapy are necessary in patients with PD-L1 expressed ESCC.

3,621 View
170 Download

Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors: Jwa Hoon Kim, Bokyung Ahn, Seung-Mo Hong, Hwoon-Yong Jung, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Jeong Hoon Lee, Hee Kyoung Na, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Sung-Bae Kim, Sook Ryun Park; Cancer Res Treat. 2022;54(2):505-516. Published online June 23, 2021; DOI: https://doi.org/10.4143/crt.2020.1198

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the real-world efficacy of immune checkpoint inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) receiving ICIs.
Materials and Methods
Sixty patients with metastatic or unresectable ESCC treated with nivolumab (n=48) or pembrolizumab (n=12) as ≥ second-line treatment between 2016 and 2019 at Asan Medical Center were included.
Results
The median age of the patients was 68 years (range, 52 to 76 years), and 93.3% were male. Most patients had metastatic disease (81.7%) and had been previously treated with fluoropyrimidines, platinum, and taxane. In 53 patients with measurable disease, the overall response rate and disease control rate were 15.1% and 35.8%, respectively. With a median follow-up duration of 16.0 months, the median progression-free survival (PFS) and overall survival (OS) were 1.9 months (95% confidence interval [CI], 1.54 to 2.19) and 6.4 months (95% CI, 4.77 to 8.11), respectively. After multivariate analysis, recent use of antibiotics, low prognostic nutrition index (< 35.93), high Glasgow Prognosis Score (≥ 1) at baseline, and ≥ 1.4-fold increase in neutrophil-to-lymphocyte ratio after one cycle from baseline were significantly unfavorable factors for both PFS and OS. Younger age (< 65 years) was a significant factor for unfavorable PFS and hyponatremia (< 135 mmol/L) for unfavorable OS.
Conclusion
The use of ICIs after the failure of chemotherapy showed comparable efficacy in patients with advanced ESCC in real practice; this may be associated with host immune-nutritional status, which could be predicted by clinical and routine laboratory factors.

Citations

Citations to this article as recorded by

Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis
Jialin Su, Yuning Li, Shuhua Tan, Tianli Cheng, Yongzhong Luo, Lemeng Zhang
Scientific Reports.2025;[Epub] CrossRef
Prognostic value of liver metastasis in patients with esophageal squamous cell carcinoma treated with nivolumab
Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi, Junichiro Itani, Daiki Sone, Naoto Iwai, Ken Inoue, Hirotaka Konishi, Osamu Dohi, Naohisa Yoshida, Atsushi Shiozaki, Kazuhiko Uchiyama, Tomohisa Takagi, Hitoshi Fujiwara, Hideyuki Konishi, Yoshito Itoh
Oncology Letters.2025;[Epub] CrossRef
Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
Yi Yu, Tao Wu, Wei Gan, Can Liu, Ran Zhang, Jinxiu Zheng, Jianping Xiong, Jun Chen, Junhe Li
Clinical and Translational Oncology.2024; 26(9): 2360. CrossRef
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety.2024; 23(6): 667. CrossRef
Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort
Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki
Esophagus.2024; 21(3): 319. CrossRef
The impact of antibiotic use in gastrointestinal tumors treated with immune checkpoint inhibitors: systematic review and meta-analysis
Faizah M. Alotaibi, Ibrahim Abdullah S. Albalawi, Amna M. Anis, Hawazin Alotaibi, Seham Khashwayn, Kanan Alshammari, Jaffar A. Al-Tawfiq
Frontiers in Medicine.2024;[Epub] CrossRef
Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases
Sho Sato, Takashi Suzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Tsutomu Sato, Takashi Kosaka, Itaru Endo, Yasushi Ichikawa, Yutaka Miyawaki, Hiroshi Sato, Hideaki Sh
Journal of Gastroenterology.2024; 59(11): 979. CrossRef
Prognostic biomarkers for immunotherapy in esophageal cancer
Xu Tong, Meiyuan Jin, Lulu Wang, Dongli Zhang, Yuping Yin, Qian Shen
Frontiers in Immunology.2024;[Epub] CrossRef
Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
Lilong Zhang, Wangbin Ma, Zhendong Qiu, Tianrui Kuang, Kunpeng Wang, Baohong Hu, Weixing Wang
Frontiers in Immunology.2023;[Epub] CrossRef
Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
Hyejee Ohm, Omar Abdel-Rahman
Current Oncology.2023; 30(1): 786. CrossRef
A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors
Athéna Crespin, Clément Le Bescop, Jean de Gunzburg, Fabien Vitry, Gérard Zalcman, Julie Cervesi, Pierre-Alain Bandinelli
Frontiers in Oncology.2023;[Epub] CrossRef
The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer
Lilong Zhang, Tianrui Kuang, Dongqi Chai, Wenhong Deng, Peng Wang, Weixing Wang
International Immunopharmacology.2023; 119: 110200. CrossRef
Predictive Impact of Prognostic Nutritional Index in Patients with Cancer Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Xin-Tian Xu, Yu Qian, Meng-Xing Tian, Chen-Chen Ding, Huan Guo, Jing Tang, Guo-Liang Pi, Yuan Wu, Zhu Dai, Xin Jin
Nutrition and Cancer.2023; 75(6): 1413. CrossRef
Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
Ning Chen, Xiaoling Xu, Yun Fan
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
進行食道癌に対する化学療法，化学放射線療法における栄養管理
豊木村
The Japanese Journal of SURGICAL METABOLISM and NUTRITION.2023; 57(6): 183. CrossRef
Prognostic and predictive impact of neutrophil‐to‐lymphocyte ratio and HLA‐I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy
Lin Wang, Yanrong Zhu, Bo Zhang, Xi Wang, Hongnan Mo, Yuchen Jiao, Jiachen Xu, Jing Huang
Thoracic Cancer.2022; 13(11): 1631. CrossRef
Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Liwei Ni, Jing Huang, Jiyuan Ding, Junyan Kou, Tingting Shao, Jun Li, Liujie Gao, Wanzhen Zheng, Zhen Wu
Frontiers in Nutrition.2022;[Epub] CrossRef
The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
Jiaxin Zhou, Guowei Huang, Wan-Ching Wong, Da-hai Hu, Jie-wen Zhu, Ruiman Li, Hong Zhou
Frontiers in Immunology.2022;[Epub] CrossRef
The prognostic value of prognostic nutritional index in advanced cancer receiving PD‐1/L1 inhibitors: A meta‐analysis
Pengfei Li, Yutian Lai, Long Tian, Qinghua Zhou
Cancer Medicine.2022; 11(16): 3048. CrossRef
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
Won Suk Lee, Dong Sung Kim, Jeong Hun Kim, Yoonki Heo, Hannah Yang, Eun-Jin Go, Jin Hyoung Kim, Seung Joon Lee, Byung Cheol Ahn, Jung Sun Yum, Hong Jae Chon, Chan Kim
Journal for ImmunoTherapy of Cancer.2022; 10(6): e004799. CrossRef
Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
Yusheng Guo, Dongqiao Xiang, Jiayu Wan, Lian Yang, Chuansheng Zheng
Cancers.2022; 14(21): 5297. CrossRef
The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Deniz Can Guven, Taha Koray Sahin, Enes Erul, Alessandro Rizzo, Angela Dalia Ricci, Sercan Aksoy, Suayib Yalcin
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
Xiaolu Ma, Yongfeng Ding, Jiong Qian, Mingyu Wan, Ning Li, Chenyu Mao, Cheng Xiao, Haiping Jiang, Yulong Zheng, Luntao Wu, Xiaoyu Chen, Nong Xu
Current Oncology.2022; 29(11): 8937. CrossRef

8,654 View
303 Download
23 Web of Science
23 Crossref

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers: Yingjia Wu, Jinbin Chen, Lei Zhao, Qiaoqiao Li, Jinhan Zhu, Hong Yang, Suping Guo, Mian Xi; Cancer Res Treat. 2021;53(1):172-183. Published online September 4, 2020; DOI: https://doi.org/10.4143/crt.2020.594

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to develop a nomogram for predicting pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) by integrating hematological biomarkers and clinicopathological characteristics.
Materials and Methods
Between 2003 and 2017, 306 ESCC patients who underwent neoadjuvant CRT followed by esophagectomy were analyzed. Besides clinicopathological factors, hematological parameters before, during, and after CRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and internally validated.
Results
Absolute lymphocyte count (ALC), lymphocyte to monocyte ratio, albumin, hemoglobin, white blood cell, neutrophil, and platelet count generally declined, whereas neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) increased significantly following neoadjuvant CRT. After surgery, 124 patients (40.5%) achieved a pCR. The pCR group demonstrated significantly more favorable survival than the non-pCR group. On multivariate analysis, significant factors associated with pCR included sex, chemotherapy regimen, post-CRT endoscopic finding, pre-CRT NLR, ALC nadir during CRT, and post-CRT PLR, which were incorporated into the prediction model. The nomogram indicated good accuracy in predicting pCR, with a C-index of 0.75 (95% confidence interval, 0.71 to 0.78).
Conclusion
Female, chemotherapy regimen of cisplatin/vinorelbine, negative post-CRT endoscopic finding, pre-CRT NLR (≤ 2.1), ALC nadir during CRT (> 0.35 ×10⁹/L), and post-CRT PLR (≤ 83.0) were significantly associated with pCR in ESCC patients treated with neoadjuvant CRT. A nomogram incorporating hematological biomarkers to predict pCR was developed and internally validated, showing good predictive performance.

Citations

Citations to this article as recorded by

CT-based deep learning radiomics and hematological biomarkers in the assessment of pathological complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma: A two-center study
Meng Zhang, Yukun Lu, Hongfu Sun, Chuanke Hou, Zichun Zhou, Xiao Liu, Qichao Zhou, Zhenjiang Li, Yong Yin
Translational Oncology.2024; 39: 101804. CrossRef
A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors
Wei-Xiang Qi, Shuyan Li, Jifeng Xiao, Huan Li, Jiayi Chen, Shengguang Zhao
Frontiers in Immunology.2024;[Epub] CrossRef
Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Ting Qian, Delin Liu, Guochun Cao, Zhipeng Chen, Qin Zhang
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
Guihong Liu, Tao Chen, Xin Zhang, Binbin Hu, Jiayun Yu
Cancer Medicine.2024;[Epub] CrossRef
Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma in Eastern versus Western countries: meta-analysis
Xing Gao, Hidde C G Overtoom, Ben M Eyck, Shi-Han Huang, Daan Nieboer, Pieter C van der Sluis, Sjoerd M Lagarde, Bas P L Wijnhoven, Yin-Kai Chao, Jan J B van Lanschot
British Journal of Surgery.2024;[Epub] CrossRef
Integrating MR radiomics and dynamic hematological factors predicts pathological response to neoadjuvant chemoradiotherapy in esophageal cancer
Yunsong Liu, Zeliang Ma, Yongxing Bao, Xin Wang, Yu Men, Xujie Sun, Feng Ye, Kuo Men, Jianjun Qin, Nan Bi, Liyan Xue, Zhouguang Hui
Heliyon.2024; 10(13): e33702. CrossRef
Preoperative neutrophil–to–lymphocyte ratio after chemoradiotherapy for esophageal squamous cell carcinoma associates with postoperative pulmonary complications following radical esophagectomy
Chien-Ming Lo, Hung-I. Lu, Yu-Ming Wang, Yen-Hao Chen, Yu Chen, Li-Chun Chen, Shau-Hsuan Li
Perioperative Medicine.2024;[Epub] CrossRef
Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery
Ji Yong Kim, Jae Kwang Yun, Yong-Hee Kim, Seung-il Park, Jeong Hoon Lee, Hwoon-Yong Jung, Gin Hyug Lee, Ho June Song, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Sung-Bae Kim, Kyung-Ja Cho, Jin-Sook Ryu, Jong Hoon Kim, Jihoon Kang, Sook Ryun Park, Hyeong Ryul
Annals of Surgical Oncology.2024; 31(10): 6662. CrossRef
The relationship between systemic immune-inflammation indexes and treatment response in locally advanced esophageal cancer
Esra KEKİLLİ, Ebru ATASEVER AKKAŞ, Serab UYAR, Emre YEKEDÜZ
Anatolian Current Medical Journal.2023; 5(1): 53. CrossRef
A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Yalan Yang, Dao Xin, Huike Wang, Lulu Guan, Xiangrui Meng, Taiying Lu, Xiwen Bai, Feng Wang
Journal of Inflammation Research.2023; Volume 16: 1443. CrossRef
Gut microbiome can predict chemoradiotherapy efficacy in patients with esophageal squamous cell carcinoma
Takuma Sasaki, Yasunori Matsumoto, Kentaro Murakami, Satoshi Endo, Takeshi Toyozumi, Ryota Otsuka, Kazuya Kinoshita, Jie Hu, Shinichiro Iida, Hiroki Morishita, Yuri Nishioka, Akira Nakano, Masaya Uesato, Hisahiro Matsubara
Esophagus.2023; 20(4): 691. CrossRef
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
Wei‐Xiang Qi, Xiaoyan Wang, Chengqiang Li, Shuyan Li, Huan Li, Feifei Xu, Jiayi Chen, Shengguang Zhao, Hecheng Li
Thoracic Cancer.2023; 14(17): 1556. CrossRef
Prognostic analysis and treatment utilization of different treatment strategies in elderly esophageal cancer patients with distant metastases: a SEER database analysis
Lian-Qiang Han, Ting-Ting Cui, Nian-Jun Xiao, Wen Li
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15413. CrossRef
Effect of dynamic platelet-to-lymphocyte ratio on the prognosis of patients with esophageal squamous cell carcinoma receiving chemoradiotherapy
Dan He, Shulan Du, Songyuan He, Hao Song, Bo Pu, Guojun Zhang, Chuan Yang
Medicine.2023; 102(49): e36554. CrossRef
Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma
Young Seob Shin, Jeong Yun Jang, Ye Jin Yoo, Jesang Yu, Kye Jin Song, Yoon Young Jo, Sung-Bae Kim, Sook Ryun Park, Ho June Song, Yong-Hee Kim, Hyeong Ryul Kim, Jong Hoon Kim
Gastroenterology Report.2023;[Epub] CrossRef
Impact of Platelets to Lymphocytes Ratio and Lymphocytes during Radical Concurrent Radiotherapy and Chemotherapy on Patients with Nonmetastatic Esophageal Squamous Cell Carcinoma
Yaotian Zhang, Ning Han, Xue Zeng, Chaonan Sun, Shichen Sun, Xinchi Ma, Yanyu Zhang, Zhuang Liu, Zilan Qin, Hong Guo, Yubing Li, Na Zhang, Bruno Vincenzi
Journal of Oncology.2022; 2022: 1. CrossRef
Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis
Liubing Hu, Jiyue Liu, Hideaki Shimada, Masaaki Ito, Kazuo Sugimoto, Takaki Hiwasa, Qinghua Zhou, Jianshuang Li, Si Shen, Hao Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma
Noel E Donlon, Maria Davern, Fiona O’Connell, Andrew Sheppard, Aisling Heeran, Anshul Bhardwaj, Christine Butler, Ravi Narayanasamy, Claire Donohoe, James J Phelan, Niamh Lynam-Lennon, Margaret R Dunne, Stephen Maher, Jacintha O’Sullivan, John V Reynolds,
World Journal of Gastroenterology.2022; 28(21): 2302. CrossRef
Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores
Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen, Xiangdong Cheng
Journal of Inflammation Research.2022; Volume 15: 3783. CrossRef
The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
Xiaoyan Sun, Yingnan Feng, Bin Zhang, Wuhao Huang, Xiaoliang Zhao, Hua Zhang, Dongsheng Yue, Changli Wang
Cancer Research and Treatment.2022; 54(4): 1017. CrossRef
The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
Jin Zhou, Hai-Ping Lin, Xin Xu, Xiao-Hang Wang, Ling Rong, Yao Zhang, Lei Shen, Lei Xu, Wei-Ting Qin, Qing Ye, Xiu-Mei Ma, Yong-Rui Bai
Frontiers in Immunology.2022;[Epub] CrossRef

7,637 View
186 Download
23 Web of Science
21 Crossref

Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities: Nai-Bin Chen, Bo Qiu, Jun Zhang, Meng-Yun Qiang, Yu-Jia Zhu, Bin Wang, Jin-Yu Guo, Ling-Zhi Cai, Shao-Min Huang, Meng-Zhong Liu, Qun Li, Yong-Hong Hu, Qi-Wen Li, Hui Liu; Cancer Res Treat. 2020;52(1):31-40. Published online April 30, 2019; DOI: https://doi.org/10.4143/crt.2018.624

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to compare the survival and toxicities in cervical esophageal squamous cell carcinoma (CESCC) treated by concurrent chemoradiothrapy with either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) techniques.
Materials and Methods
A total of 112 consecutive CESCC patients were retrospectively reviewed. 3D-CRT and IMRT groups had been analyzed by propensity score matching method, with sex, age, Karnofsky performance status, induction chemotherapy, and tumor stage well matched. The Kaplan-Meier method and Cox proportional hazards model were used for overall survival (OS) and progression-free survival (PFS). Toxicities were compared between two groups by Fisher exact test.
Results
With a median follow-up time of 34.9 months, the 3-year OS (p=0.927) and PFS (p=0.859) rate was 49.6% and 45.8% in 3D-CRT group, compared with 54.4% and 42.8% in IMRT group. The rates of grade ≥ 3 esophagitis, grade ≥ 2 pneumonitis, esophageal stricture, and hemorrhage were comparable between two groups, while the rate of tracheostomy dependence was much higher in IMRT group than 3D-CRT group (14.3% vs.1.8%, p=0.032). Radiotherapy technique (hazard ratio [HR], 0.09; 95% confidence interval [CI], 0.01 to 0.79) and pretreatment hoarseness (HR, 0.12; 95% CI 0.02 to 0.70) were independently prognostic of tracheostomy dependence.
Conclusion
No survival benefits had been observed while comparing IMRT versus 3D-CRT in CESCC patients. IMRT with fraction dose escalation and pretreatment hoarseness were considered to be associated with a higher risk for tracheostomy dependence. Radiation dose escalation beyond 60 Gy should be taken into account carefully when using IMRT with hypofractionated regimen.

Citations

Citations to this article as recorded by

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma
Renxian Xie, Qingxin Cai, Tong Chen, Hongxin Huang, Chuangzhen Chen
Frontiers in Oncology.2024;[Epub] CrossRef
Tumor-Derived Exosomal miR-143-3p Induces Macrophage M2 Polarization to Cause Radiation Resistance in Locally Advanced Esophageal Squamous Cell Carcinoma
Lin-Rui Gao, Jiajun Zhang, Ning Huang, Wei Deng, Wenjie Ni, Zefen Xiao, Mei Liu
International Journal of Molecular Sciences.2024; 25(11): 6082. CrossRef
Dose escalation in radical radio(chemo)therapy for cervical and upper thoracic esophageal cancer with 3DCRT/IMRT (ChC&UES): a multicenter retrospective study
Xiao-Han Zhao, Wen-Cheng Zhang, Xin Wang, Jun-Qiang Chen, Yuan-Ji Xu, Kuai-Le Zhao, Wei Huang, Pu-Dong Qian, Ya-Tian Liu, Xiao-Lin Ge, Xiao-Jie Xia, Chen-Gang Weng, Chun-Yue Gai, He-Song Wang, Hong-Mei Gao, Wen-Bin Shen, Shu-Chai Zhu
Radiation Oncology.2024;[Epub] CrossRef
Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Journal of Cancer Research and Clinical Oncology.2023; 149(3): 1029. CrossRef
Effect of preoperative radiotherapy on the prognosis of patients with stage cTxN0M0 esophageal squamous cell carcinoma: propensity score matching analysis based on SEER database
Zixian Jin, Jiajing Sun, Jian Zhang, Jianfei Shen, Bo Zhang
Frontiers in Surgery.2023;[Epub] CrossRef
Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial
Hui Li, Ying Fang, Dayong Gu, Mingyu Du, Zhi Zhang, Lei Sun, Guoren Zhou, Jinjun Ye
Radiation Oncology.2022;[Epub] CrossRef
A Retrospective Study of Chemotherapy and 3D-Image-Guided Afterloading Intracavitary Radiotherapy in Locally Advanced Cervical Cancer
Xiaojun Li, Cunlian An, Chunlan Feng, Jieren Sun, Huixiang Lu, Xiaodong Yang, Kaiping Wang, Ruimei Wang, Zhongjie Shi
Journal of Oncology.2022; 2022: 1. CrossRef
Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
Siran Yang, Wenqing Wang, Nan Bi, Zongmei Zhou, Qinfu Feng, Zefen Xiao, Dongfu Chen, Jun Liang, Jima Lu, Jianyang Wang, Xin Wang, Jingbo Wang, Yong Yang, Ningning Lu, Hongxing Zhang, Luhua Wang
Medicine.2022; 101(42): e31215. CrossRef
Outcome of chemoradiotherapy using intensity-modulated radiation therapy for cervical esophageal cancer: a single institute experience
Masahiro Inada, Yasumasa Nishimura, Kazuki Ishikawa, Takuya Uehara, Yutaro Wada, Yasuo Oguma, Hiroshi Doi, Kiyoshi Nakamatsu
Esophagus.2021; 18(3): 638. CrossRef
Radiation-induced acute injury of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a prospective cohor
Zexin Yao, Bing Zhang, Jialin Huang, Lei Shi, Biao Cheng
Scientific Reports.2021;[Epub] CrossRef
Correlation between the γ passing rates of IMRT plans and the volumes of air cavities and bony structures in head and neck cancer
Zhengwen Shen, Xia Tan, Shi Li, Xiumei Tian, Huanli Luo, Ying Wang, Fu Jin
Radiation Oncology.2021;[Epub] CrossRef
Rehabilitation Nursing Intervention Can Improve Dysphagia and Quality of Life of Patients Undergoing Radiotherapy for Esophageal Cancer
Xiange Zeng, Ling Li, Wenjing Wang, Lihui Zhu, Alamgeer Yuchi
Journal of Oncology.2021; 2021: 1. CrossRef
Late Toxicities, Failure Patterns, Local Tumor Control, and Survival of Esophageal Squamous Cell Carcinoma Patients After Chemoradiotherapy With a Simultaneous Integrated Boost: A 5-Year Phase II Study
Chuangzhen Chen, Jianzhou Chen, Ting Luo, Siyan Wang, Hong Guo, Chengbing Zeng, Yanxuan Wu, Weitong Liu, Ruihong Huang, Tiantian Zhai, Zhijian Chen, Derui Li
Frontiers in Oncology.2021;[Epub] CrossRef
Conformal radiation therapy versus volumetric arc therapy in high dose concurrent chemoradiotherapy for carcinoma esophagus
Tapas Kumar Dora, Jayashree Deshmukh, Abhishek Chatterjee, Alok Goel, Subhadeep Bose, Avtar Singh, Amit Saini, Shefali Pahwa, Sarbani Ghosh Laskar, Jai Prakash Agarwal, Shyam Kishore Shrivastava, Rakesh Kapoor
Cancer Research, Statistics, and Treatment.2021; 4(3): 456. CrossRef
Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy
Kaiqi Lan, Jinhan Zhu, Jun Zhang, Sha Zhou, Yadi Yang, Zizhen Feng, Li Zhang, Shi Wang, Mian Xi
Radiotherapy and Oncology.2020; 149: 228. CrossRef
LINC00473 contributes to the radioresistance of esophageal squamous cell carcinoma by regulating microRNA‑497‑5p and cell division cycle 25A
Wei‑Hua Liu, Han‑Yong Qiao, Jian Xu, Wei‑Qing Wang, Yi‑Lei Wu, Xia Wu
International Journal of Molecular Medicine.2020; 46(2): 571. CrossRef
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol
Lin-rui Gao, Xin Wang, Weiming Han, Wei Deng, Chen Li, Xiaomin Wang, Yidian Zhao, Wenjie Ni, Xiao Chang, Zongmei Zhou, Lei Deng, Wenqing Wang, Wenyang Liu, Jun Liang, Tao Zhang, Nan Bi, Jianyang Wang, Yirui Zhai, Qinfu Feng, Jima Lv, Ling Li, Zefen Xiao
BMC Cancer.2020;[Epub] CrossRef

7,673 View
253 Download
20 Web of Science
17 Crossref

Preclinical Study of Novel Curcumin Analogue SSC-5 Using Orthotopic Tumor Xenograft Model for Esophageal Squamous Cell Carcinoma: Lai Nar Tung, Senchuan Song, Kin Tak Chan, Mei Yuk Choi, Ho Yu Lam, Chung Man Chan, Zhiyong Chen, Hector K. Wang, Hoi Ting Leung, Simon Law, Yanmin Huang, Huacan Song, Nikki P. Lee; Cancer Res Treat. 2018;50(4):1362-1377. Published online January 24, 2018; DOI: https://doi.org/10.4143/crt.2017.353

Abstract PDF PubReader ePub

Purpose
Tumor xenograft model is an indispensable animal cancer model. In esophageal squamous cell carcinoma (ESCC) research, orthotopic tumor xenograft model establishes tumor xenograft in the animal esophagus, which allows the study of tumorigenesis in its native microenvironment.
Materials and Methods
In this study,we described two simple and reproducible methods to develop tumor xenograft at the cervical or the abdominal esophagus in nude mice by direct injection of ESCC cells in the esophageal wall.
Results
In comparing these two methods, the cervical one presented with more clinically relevant features, i.e., esophageal stricture, body weight loss and poor survival. In addition, the derived tumor xenografts accompanied a rapid growth rate and a high tendency to invade into the surrounding structures. This model was subsequently used to study the anti-tumor effect of curcumin, which is known for its potential therapeutic effects in various diseases including cancers, and its analogue SSC-5. SSC-5 was selected among the eight newly synthesized curcumin analogues based on its superior anti-tumor effect demonstrated in an MTT cell proliferation assay and its effects on apoptosis induction and cell cycle arrest in cultured ESCC cells. Treatment of orthotopic tumor-bearing mice with SSC-5 resulted in an inhibition in tumor growth and invasion.
Conclusion
Taken together, we have established a clinically relevant orthotopic tumor xenograft model that can serve as a preclinical tool for screening new anti-tumor compounds, e.g., SSC-5, in ESCC.

Citations

Citations to this article as recorded by

Network pharmacology and molecular docking reveal the mechanisms of curcumin activity against esophageal squamous cell carcinoma
Jian Wang, Zhilong Zhang, Qian Li, Zilong Hu, Yuan Chen, Hao Chen, Wei Cai, Qiancheng Du, Peng Zhang, Dian Xiong, Shugao Ye
Frontiers in Pharmacology.2024;[Epub] CrossRef
Curcumin: recent updates on gastrointestinal cancers
Muhammad Imran, Farhan Saeed, Suliman A. Alsagaby, Ali Imran, Ishtiaque Ahmad, Ahmad H. El Ghorab, Mohamed A. Abdelgawad, Tahira Batool Qaisrani, Tahir Mehmood, Maryam Umar, Muhammad Arslan Mumtaz, Arfaa Sajid, Qaisar Manzoor, Muzzamal Hussain, Waleed Al
CyTA - Journal of Food.2023; 21(1): 502. CrossRef
The anticancer effects of curcumin and clinical research progress on its effects on esophageal cancer
Shimeng Wang, Xinliang Gao, Jialin Li, Shixiong Wei, Yifeng Shao, Yipeng Yin, Duo Zhang, Mingbo Tang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review
Korosh Morshedi, Sarina Borran, Mohammad Saeid Ebrahimi, Mohammad Jaber Masoud khooy, Zeynab Sadat Seyedi, Atefeh Amiri, Mohammad Abbasi‐Kolli, Maryam Fallah, Haroon Khan, Amirhossein Sahebkar, Hamed Mirzaei
Phytotherapy Research.2021; 35(9): 4834. CrossRef
Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
Shoh Yajima, Kotaro Sugawara, Miwako Iwai, Minoru Tanaka, Yasuyuki Seto, Tomoki Todo
Molecular Therapy - Oncolytics.2021; 23: 402. CrossRef
Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status
AmirReza Hesari, Mitra Azizian, Alireza Sheikhi, Abolfazl Nesaei, Shahin Sanaei, Nazanin Mahinparvar, Maryam Derakhshani, Pegah Hedayt, Faezeh Ghasemi, Hamed Mirzaei
International Journal of Cancer.2019; 144(6): 1215. CrossRef
Latest in Vitro and in Vivo Assay, Clinical Trials and Patents in Cancer Treatment using Curcumin: A Literature Review
Kevin Doello, Raúl Ortiz, Pablo J. Alvarez, Consolación Melguizo, Laura Cabeza, José Prados
Nutrition and Cancer.2018; 70(4): 569. CrossRef
Tumor xenograft animal models for esophageal squamous cell carcinoma
Nikki P. Lee, Chung Man Chan, Lai Nar Tung, Hector K. Wang, Simon Law
Journal of Biomedical Science.2018;[Epub] CrossRef

10,409 View
263 Download
11 Web of Science
8 Crossref

Downregulation of HuR Inhibits the Progression of Esophageal Cancer through Interleukin-18: Xiaohui Xu, Cheng Song, Zhihua Chen, Chenxiao Yu, Yi Wang, Yiting Tang, Judong Luo; Cancer Res Treat. 2018;50(1):71-87. Published online February 24, 2017; DOI: https://doi.org/10.4143/crt.2017.013

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the effect of human antigen R (HuR) downregulation and the potential target genes of HuR on the progression of esophageal squamous cell carcinoma (ESCC).
Materials and Methods
In this study, a proteomics assay was used to detect the expression of proteins after HuR downregulation, and a luciferase assay was used to detect the potential presence of a HuR binding site on the 3’-untranslated region (3'-UTR) of interleukin 18 (IL-18). In addition, colony formation assay, MTT, EdU incorporation assay, Western blot, flow cytometry, immunohistochemistry, transwell invasion assay, and wound healing assay were used.
Results
In the present study, we found that the expression of both HuR protein and mRNA levels were higher in tumor tissues than in the adjacent tissues. HuR downregulation significantly suppressed cell proliferation. In addition, the metastasis of esophageal cancer cells was inhibited, while the expression of E-cadherin was increased and the expression of matrix metalloproteinase (MMP) 2, MMP9, and vimentin was decreased after HuR knockdown. Moreover, silencing of HuR disturbed the cell cycle of ESCC cells mainly by inducing G1 arrest. Furthermore, proteomics analysis showed that downregulation of HuR in TE-1 cells resulted in 100 upregulated and 122 downregulated proteins, including IL-18 as a significantly upregulated protein. The expression of IL-18 was inversely regulated by HuR. IL-18 expression was decreased in ESCC tissues, and exogenous IL-18 significantly inhibited the proliferation and metastasis of ESCC cells. The 3'-UTR of IL-18 harbored a HuR binding site, as shown by an in vitro luciferase assay.
Conclusion
HuR plays an important role in the progression of esophageal carcinoma by targeting IL-18, which may be a potential therapeutic target for the treatment of ESCC.

Citations

Citations to this article as recorded by

Mechanistic insights into the antitumoral potential and in vivo antiproliferative efficacy of a silver-based core@shell nanosystem
Guillermo Aragoneses-Cazorla, Roberto Alvarez-Fernandez Garcia, Angelica Martinez-Lopez, Milagros Gomez Gomez, Maria Vallet-Regí, Sonia Castillo-Lluva, Blanca González, Jose L. Luque-Garcia
International Journal of Pharmaceutics.2024; 655: 124023. CrossRef
Blocking SLC7A11 attenuates the proliferation of esophageal squamous cell carcinoma cells
Wen-Ting Li, Xin Jin, Sheng-Jie Song, Chong Wang, Chuang Fu, Wen Jiang, Jie Bai, Zhi-Zhou Shi
Animal Cells and Systems.2024; 28(1): 237. CrossRef
Editorial: Radiotherapy for esophageal cancer: Molecular mechanism and novel targets to improve radiosensitivity
Yanqing Liu, Adam Yongxin Ye, Jordan Lu, Jiaxing Yang, Xiao Zheng, Xiaodong Li
Frontiers in Oncology.2023;[Epub] CrossRef
HuR Affects the Radiosensitivity of Esophageal Cancer by Regulating the EMT-Related Protein Snail
Yan Hu, Qing Li, Ke Yi, Chi Yang, Qingjun Lei, Guanghui Wang, Qianyun Wang, Xiaohui Xu
Frontiers in Oncology.2022;[Epub] CrossRef
Identification of a Novel Pyroptosis-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Skin Cutaneous Melanoma
An-An Li, Yu Zhang, Wei-Lai Tong, Jiang-Wei Chen, Shan-Hu Huang, Jia-Ming Liu, Zhi-Li Liu
International Journal of General Medicine.2022; Volume 15: 6145. CrossRef
MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes
Cyril Sobolewski, Laurent Dubuquoy, Noémie Legrand
Cancers.2022; 14(14): 3516. CrossRef
The role of human antigen R (HuR) in modulating proliferation, senescence and radiosensitivity of skin cells
Daojiang Yu, Yahui Feng, Zhiqiang Jiang, Tao Yan, Kai Fang, Yuhong Shi, Jie Zhang, Shuyu Zhang
Experimental and Therapeutic Medicine.2022;[Epub] CrossRef
IFI35 is involved in the regulation of the radiosensitivity of colorectal cancer cells
Yan Hu, Bing Wang, Ke Yi, Qingjun Lei, Guanghui Wang, Xiaohui Xu
Cancer Cell International.2021;[Epub] CrossRef
LncRNA BBOX1‐AS1 upregulates HOXC6 expression through miR‐361‐3p and HuR to drive cervical cancer progression
Jun Xu, Baohua Yang, Lifeng Wang, Yunheng Zhu, Xiuxiang Zhu, Ziyin Xia, Zhen Zhao, Ling Xu
Cell Proliferation.2020;[Epub] CrossRef
Angustoline Inhibited Esophageal Tumors Through Regulating LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid Remodeling
Huiying Li, Cheng Zhang, Min Zhang, Qianqian Yao, Huaigu Yang, Linlin Fan, Nan Zheng
Frontiers in Oncology.2020;[Epub] CrossRef
The RNA‐Binding Protein HuR in Digestive System Tumors
Xiaoqing Song, Xin Shi, Wenjuan Li, Fa Zhang, Zhonglin Cai, Goutam Ghosh Choudhury
BioMed Research International.2020;[Epub] CrossRef
Proteogenomic examination of esophageal squamous cell carcinoma (ESCC): new lines of inquiry
Shobha Dagamajalu, Manavalan Vijayakumar, Rohan Shetty, D. A. B. Rex, Chinmaya Narayana Kotimoole, T. S. Keshava Prasad
Expert Review of Proteomics.2020; 17(9): 649. CrossRef
Interleukin-18 Is a Prognostic Marker and Plays a Tumor Suppressive Role in Colon Cancer
Xiaodong Feng, Zhijun Zhang, Peng Sun, Guanghui Song, Lu Wang, Zhenqing Sun, Ning Yuan, Qing Wang, Limin Lun, Roberta Rizzo
Disease Markers.2020; 2020: 1. CrossRef
Proteomics in Drug Development: The Dawn of a New Era?
Maria Frantzi, Agnieszka Latosinska, Harald Mischak
PROTEOMICS – Clinical Applications.2019;[Epub] CrossRef
IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas
Guanglin Cui, Zhenfeng Li, Jingli Ren, Aping Yuan
Virchows Archiv.2019; 475(5): 579. CrossRef
The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer
Man Wang, Shuai Jiang, Yinfeng Zhang, Peifeng Li, Kun Wang
Cancers.2019; 11(9): 1313. CrossRef
Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells
Zili Zhang, Zhen Yao, Ling Wang, Hai Ding, Jiangjuan Shao, Anping Chen, Feng Zhang, Shizhong Zheng
Autophagy.2018; 14(12): 2083. CrossRef
Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8+T Cells and NK Cells
Jiantao Li, Gang Qiu, Baoshuan Fang, Xiaohui Dai, Jianhui Cai
Inflammation.2018; 41(2): 667. CrossRef

11,854 View
300 Download
22 Web of Science
18 Crossref

Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE₂: Ivan Ho Yuen Pun, Dessy Chan, Sau Hing Chan, Po Yee Chung, Yuan Yuan Zhou, Simon Law, Alfred King Yin Lam, Chung Hin Chui, Albert Sun Chi Chan, Kim Hung Lam, Johnny Cheuk On Tang; Cancer Res Treat. 2017;49(1):219-229. Published online July 18, 2016; DOI: https://doi.org/10.4143/crt.2016.190

Abstract PDF Supplementary Material PubReader ePub

Purpose
83b1 is a novel quinoline derivative that has been shown to inhibit cancer growth in human esophageal squamous cell carcinoma (ESCC). This study was conducted to comprehensively evaluate the cytotoxic effects of 83b1 on a series of ESCC cell lines and investigate the mechanisms by which 83b1 suppresses cancer growth based on molecular docking analysis.
Materials and Methods
A series of ESCC and nontumor immortalized cell lines were exposed to 83b1 and cisplatin (CDDP) in a dose-dependent manner, and the cytotoxicity was examined by a MTS assay kit. Prediction of the molecular targets of 83b1 was conducted by molecular docking analysis. Expression of cyclooxygenase 2 (COX-2) mRNA and COX-2–derived prostaglandin E2 (PGE2) were measured by quantitative real-time polymerase chain reaction and enzymelinked immuno-sorbent assay, respectively. In vivo anti-tumor effect was determined using a nude mice xenografted model transplanted with an ESCC cell line, KYSE-450.
Results
83b1 showed the significant anti-cancer effects on all ESCC cell lines compared to CDDP; however, 83b1 revealed much lower toxic effects on non-tumor cell lines than CDDP. The predicted molecular target of 83b1 is peroxisome proliferator-activated receptor delta (PPARδ), which is a widely known oncoprotein. Additionally the expression of COX-2 mRNA and COX-2–derived PGE2 were down-regulated by 83b1 in a dose-dependent manner in ESCC cell lines. Furthermore, 83b1 was shown to significantly reduce the tumor size in nude mice xenograft.
Conclusion
The results of this study suggest that the potential anti-cancer effects of 83b1 on human esophageal cancers occur through the possible oncotarget, PPARδ, and down-regulation of the cancer related genes and molecules.

Citations

Citations to this article as recorded by

Synthesis and biological evaluation of novel 2-morpholino-4-anilinoquinoline derivatives as antitumor agents against HepG2 cell line
Ahmed Al-Sheikh, Malak A. Jaber, Hana'a Khalaf, Nour AlKhawaja, Duaa Abuarqoub
RSC Advances.2024; 14(5): 3304. CrossRef
Natural alkaloids as potential treatments for esophageal squamous-cell carcinoma: A comprehensive review
Eugene Jamot Ndebia, Gabriel Tchuente Kamsu
Gastroenterology & Endoscopy.2024; 2(3): 131. CrossRef
Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
Molecular and Cellular Biochemistry.2024;[Epub] CrossRef
Downregulation of chemokine (C‑C motif) ligand 5 induced by a novel 8‑hydroxyquinoline derivative (91b1) suppresses tumor invasiveness in esophageal carcinoma
Johnny Tang, Dessy Chan, Po-Yee Chung, Yijiang Liu, Alfred Lam, Simon Law, Wolin Huang, Albert Chan, Kim-Hung Lam, Yuanyuan Zhou
International Journal of Molecular Medicine.2024;[Epub] CrossRef
Peroxisome proliferator-activated receptors regulate the progression and treatment of gastrointestinal cancers
Min Zhang, Shujie He
Frontiers in Pharmacology.2023;[Epub] CrossRef
Roles of Nuclear Receptors in Esophageal Cancer
Lihao Deng, Jiaxuan Liu, Wei-Dong Chen, Yan-Dong Wang
Current Pharmaceutical Biotechnology.2023; 24(12): 1489. CrossRef
Synthesis and biological activities of new phthalimide and thiazolidine derivatives
Flaviana A. Santos, Marcel L. Almeida, Vitor A. S. Silva, Douglas C. F. Viana, Michelly C. Pereira, André S. L. Lucena, Maira G. R. Pitta, Marina R. Galdino-Pitta, Moacyr J. B. de Melo Rêgo, Ivan da Rocha Pitta
Medicinal Chemistry Research.2022; 31(1): 108. CrossRef
Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer
David Jay Wilson, Raymond N. DuBois
Cancer Prevention Research.2022; 15(6): 355. CrossRef
The Anticancer Effect of a Novel Quinoline Derivative 91b1 through Downregulation of Lumican
Yuanyuan Zhou, Zhongguo Zhou, Dessy Chan, Po yee Chung, Yongqi Wang, Albert Sun chi Chan, Simon Law, Kim hung Lam, Johnny Cheuk On Tang
International Journal of Molecular Sciences.2022; 23(21): 13181. CrossRef
Synthesis and biological evaluations of N′-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents
Baicun Li, Feifeng Zhu, Fengming He, Qingqing Huang, Xiaoguang Liu, Tong Wu, Taige Zhao, Yingkun Qiu, Zhen Wu, Yuhua Xue, Meijuan Fang
Bioorganic Chemistry.2020; 96: 103592. CrossRef
Feasibility of Repurposing Clioquinol for Cancer Therapy
Raheel Khan, Harras Khan, Yassen Abdullah, Q. Ping Dou
Recent Patents on Anti-Cancer Drug Discovery.2020; 15(1): 14. CrossRef
DFIQ, a Novel Quinoline Derivative, Shows Anticancer Potential by Inducing Apoptosis and Autophagy in NSCLC Cell and In Vivo Zebrafish Xenograft Models
Hurng-Wern Huang, Yung-Ding Bow, Chia-Yih Wang, Yen-Chun Chen, Pei-Rong Fu, Kuo-Feng Chang, Tso-Wen Wang, Chih-Hua Tseng, Yeh-Long Chen, Chien-Chih Chiu
Cancers.2020; 12(5): 1348. CrossRef
Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds
Hongbin Huang, Guigui Zhang, Yuquan Zhou, Chenru Lin, Suling Chen, Yutong Lin, Shangkang Mai, Zunnan Huang
Frontiers in Chemistry.2018;[Epub] CrossRef
The roles of the COX2/PGE2/EP axis in therapeutic resistance
Dali Tong, Qiuli Liu, Lin-ang Wang, Qiubo Xie, Jian Pang, Yiqiang Huang, Luofu Wang, Gaolei Liu, Dianzheng Zhang, Weihua Lan, Jun Jiang
Cancer and Metastasis Reviews.2018; 37(2-3): 355. CrossRef
Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma
Dessy Chan, Yuanyuan Zhou, Chung Hin Chui, Kim Hung Lam, Simon Law, Albert Sun-chi Chan, Xingshu Li, Alfred King-yin Lam, Johnny Cheuk On Tang
Cells.2018; 7(10): 143. CrossRef
Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma
Po Chung, Pik Lam, Yuanyuan Zhou, Jessica Gasparello, Alessia Finotti, Adriana Chilin, Giovanni Marzaro, Roberto Gambari, Zhaoxiang Bian, Wai Kwok, Wai Wong, Xi Wang, Alfred Lam, Albert Chan, Xingshu Li, Jessica Ma, Chung Chui, Kim Lam, Johnny Tang
Cells.2018; 7(10): 177. CrossRef

11,093 View
255 Download
20 Web of Science
16 Crossref

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Hyun Ae Jung, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im; Cancer Res Treat. 2013;45(4):285-294. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.285

Abstract PDF PubReader ePub

PURPOSE
The degree of benefit from palliative chemotherapy differs widely among patients with metastatic esophageal squamous cell carcinoma (MESCC). The purpose of this study was to develop and validate a prognostic nomogram to predict survival and aid physicians and patients in the decision-making process regarding treatment options.
MATERIALS AND METHODS
Clinicopathologic variables and treatment outcomes of 239 patients who were diagnosed with MESCC and received either fluorouracil/cisplatin (FP) or capecitabine/cisplatin (XP) as first-line chemotherapy were reviewed. A nomogram was developed as a prognostic scoring system incorporating significant clinical and laboratory variables based on a multivariate Cox proportional hazards regression model. An independent series of 61 MESCC patients treated with FP served as an independent data set for nomogram validation.
RESULTS
No difference in response rate was observed between the FP group (44.8%) and the XP group (54.2%). Similarly, no significant differences in median progression-free survival and median overall survival were observed between regimen groups. Multivariate analysis showed that poor performance status (Eastern Cooperative Oncology Group [ECOG] status> or =2), weight loss (10% of the weight loss for 3 months), low albumin level (< or =3.5 g/dL), and absence of previous esophagectomy at the time of chemotherapy were significantly associated with low OS in both groups (p<0.05). Based on these findings, patients were classified into favorable (score, 0 to 90), intermediate (91-134), and poor (>135) prognostic groups. The median survival for those with a favorable ECOG was 13.8 months (95% confidence interval [CI], 10.8 to 18.6 months), for intermediate 11.2 months (95% CI, 8.7 to 11.9 months), and for poor, 7.0 months (95% CI, 3.6 to 10.0 months). External validation of the nomogram in a different patient cohort yielded significantly similar findings.
CONCLUSION
The nomogram described here predicts survival in MESCC patients and could serve as a guide for the use of FP/XP chemotherapy in MESCC patients.

Citations

Citations to this article as recorded by

A population-based investigation: How to identify high-risk T1-2N0 esophageal cancer patients?
Peng Luo, Jie Wu, Xiankai Chen, Yafan Yang, Ruixiang Zhang, Xiuzhu Qi, Yin Li
Frontiers in Surgery.2023;[Epub] CrossRef
Low-Dose Versus High-Dose Radiation Therapy for the Palliation of Dysphagia From Esophageal Cancer: A Multicenter Retrospective Cohort Study
Bram D. Vermeulen, Paul M. Jeene, Jasmijn Sijben, Robin Krol, Heidi Rütten, Johannes A. Bogers, Pètra M. Braam, Peter D. Siersema
Practical Radiation Oncology.2020; 10(4): e255. CrossRef
Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
Qingxia Fu, Jiancheng Wang, Hong Liu
Drug Delivery.2020; 27(1): 1535. CrossRef
A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study
Xin Tang, Xiaojuan Zhou, Yanying Li, Xue Tian, Yongsheng Wang, Meijuan Huang, Li Ren, Lin Zhou, Zhenyu Ding, Jiang Zhu, Yong Xu, Feng Peng, Jin Wang, You Lu, Youling Gong
Annals of Surgical Oncology.2019; 26(2): 321. CrossRef
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
Héctor van den Boorn, Ameen Abu-Hanna, Emil ter Veer, Jessy van Kleef, Florian Lordick, Michael Stahl, Jaffer Ajani, Rosine Guimbaud, Se Park, Susan Dutton, Yung-Jue Bang, Narikazu Boku, Nadia Mohammad, Mirjam Sprangers, Rob Verhoeven, Aeilko Zwinderman,
Cancers.2019; 11(2): 187. CrossRef
Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Yuji Murakami, Ikuno Nishibuchi, Yuta Ibuki, Ichiko Yamakita, Tomoaki Kurokawa, Yasushi Nagata, Morihito Okada
World Journal of Surgery.2018; 42(5): 1496. CrossRef
Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis
H. G. van den Boorn, E. G. Engelhardt, J. van Kleef, M. A. G. Sprangers, M. G. H. van Oijen, A. Abu-Hanna, A. H. Zwinderman, V. M. H. Coupé, H. W. M. van Laarhoven, Masaru Katoh
PLOS ONE.2018; 13(2): e0192310. CrossRef
Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review
Vaibhav Gupta, Natalie Coburn, Biniam Kidane, Kenneth R. Hess, Carolyn Compton, Jolie Ringash, Gail Darling, Alyson L. Mahar
The Journal of Thoracic and Cardiovascular Surgery.2018; 156(2): 847. CrossRef
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control
Nuria Kotecki, Sandrine Hiret, Pierre-Luc Etienne, Nicolas Penel, Emmanuelle Tresch, Eric François, Marie Pierre Galais, Meher Ben Abdelghani, Pierre Michel, Laetitia Dahan, François Ghiringelli, Laurent Bedenne, Emmanuelle Samalin, Guillaume Piessen, Jaf
Oncology.2016; 90(2): 88. CrossRef
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
Michael W. Kattan, Cora N. Sternberg, Faisal Mehmud, Kamal Bhatt, Lauren McCann, Robert J. Motzer
Oncology.2015; 89(4): 235. CrossRef
Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Hyun Ae Jung, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im
Cancer Research and Treatment.2013; 45(4): 285. CrossRef

11,771 View
88 Download
11 Crossref

Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy: Dae-Eun Kim, Uh-Jin Kim, Won-Young Choi, Mi-Young Kim, Seung-Hun Kim, Min-Jee Kim, Hyun-Jeong Shim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung, Taek-Keun Nam, Kook-Joo Na, Sang-Hee Cho; Cancer Res Treat. 2013;45(4):276-284. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.276

Abstract PDF PubReader ePub

PURPOSE
Locally advanced esophageal cancers are generally treated with neoadjuvant chemoradiotherapy, followed by surgery in operable candidates. However, even if the patients were diagnosed as operable disease, surgery could not be performed on patients with poor condition or other comorbidity. In this case, definitive chemoradiotherapy (dCRT) is the other option for localized esophageal cancer. Therefore, the purpose of this study was to evaluate the efficacy and clinical prognostic factors for dCRT in locally advanced esophageal cancer.
MATERIALS AND METHODS
We conducted a review of patients who received dCRT for locally advanced squamous esophageal cancer from 2004 to 2010, focusing on stages III and IVa. All patients received at least two cycles of platinum-based chemotherapy during radiation, and all tumor burdens were included in the radiation field. The treatment results were analyzed for patterns of failure and prognostic factors associated with survival.
RESULTS
In total, 63 patients were enrolled in this study. The overall response rate was 84.1%. Relief from dysphagia after dCRT was achieved in 48 patients. The most frequent failure was local recurrence. The median overall survival (OS) was 23.0 months, and the 2-year survival rate was 45.4%. Similar results were observed for elderly study patients. Significant prognostic factors for OS were duration of smoking, high grade of dysphagia (score of 3 or 4), and shorter duration of progression-free and dysphagia-free survival. Maintenance chemotherapy after dCRT did not influence OS. However, "good risk" patients receiving maintenance chemotherapy showed better OS than those who did not receive maintenance chemotherapy (30.4 months vs. 12.0 months, p=0.002).
CONCLUSION
dCRT has a major role in improving survival and palliation of dysphagia in inoperable advanced esophageal cancer, even in elderly patients. Maintenance chemotherapy after dCRT may be effective in prolonging survival in "good risk" patients.

Citations

Citations to this article as recorded by

Maintenance chemotherapy for esophageal squamous cell carcinoma after standard concurrent chemoradiotherapy: a national propensity score matching cohort study
Szu-Wen Tseng
American Journal of Cancer Research.2024; 14(5): 2300. CrossRef
Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT
Geng Xiang, Chunsheng Xu, Guangjin Chai, Bo Lyu, Zhaohui Li, Bin Wang, Mei Shi, Lina Zhao
Radiation Oncology.2023;[Epub] CrossRef
Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis
Q. Gao, Z.-Y. Liu, Y. Cheng, X.-K. Di, Y.-M. Zhang, X.-C. Sun, X.-J. Xia, X.-L. Ge
Cancer/Radiothérapie.2022; 26(8): 1002. CrossRef
Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K/AKT/FOXO3A signaling pathway in ESCC
Xingyu Du, Xueyuan Zhang, Jing Dong, Naiyi Zou, Dong Guo, Weinan Yao, Xiaobin Wang, Shuguang Li, Chunyang Song, Ke Yan, Wenbin Shen, Shuchai Zhu
Journal of Translational Medicine.2022;[Epub] CrossRef
A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma
X. Xia, Z. Liu, B. Cai, X. Di, X. Sun, X. Ge
Cancer/Radiothérapie.2021; 25(1): 39. CrossRef
Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis
Xiaojie Xia, Zeyuan Liu, Qin Qin, Xiaoke Di, Zhaoyue Zhang, Xinchen Sun, Xiaolin Ge
Frontiers in Oncology.2021;[Epub] CrossRef
High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis
Baoqing Chen, Meiling Deng, Chen Yang, Mihnea P. Dragomir, Lei Zhao, Kunhao Bai, Mian Xi, Yonghong Hu, Yujia Zhu, Qiaoqiao Li
Radiotherapy and Oncology.2021; 158: 191. CrossRef
Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Jun Gi Yeom, Jie-Hyun Kim, Jun Won Kim, Yeona Cho, Ik Jae Lee, Chang Geol Lee, Jaeyoung Chun, Young Hoon Youn, Hyojin Park
Cancers.2021; 13(6): 1255. CrossRef
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
Xi-Lei Zhou, Chang-Hua Yu, Wan-Wei Wang, Fu-Zhi Ji, Yao-Zu Xiong, Wei-Guo Zhu, Yu-Suo Tong
Radiation Oncology.2021;[Epub] CrossRef
Clinical Outcomes and Prognostic Factors of Salvage Treatment for Local Lymph Node Recurrence After Radical Resection of Oesophageal Carcinoma
Liang Gu, Yangchen Liu, Hongxue Ye, Fei Gao, Xiaoxiang Yin, Ying Zhao, Ye Tian
Cancer Management and Research.2021; Volume 13: 5845. CrossRef
Chemoradiotherapy Is Superior to Radiotherapy Alone in Esophageal Cancer Patients Older Than 65 Years: A Propensity Score-Matched Analysis of the SEER Database
Xiaojie Xia, Qing Gao, Xiaolin Ge, Zeyuan Liu, Xiaoke Di, Xinchen Sun, Yan Yang
Frontiers in Oncology.2021;[Epub] CrossRef
Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis
Jianing Wang, Linlin Xiao, Shuai Wang, Qingsong Pang, Jun Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients
Ao Liu, Yalin Wang, Xin Wang, Liqiong Zhu, Yu Nie, Minghuan Li
Radiation Oncology.2021;[Epub] CrossRef
Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
An-Du Zhang, Xiao-Hua Su, Gao-Feng Shi, Chun Han, Lan Wang, Hui Liu, Jun Zhang, Ruo-Hui Zhang
Archives of Medical Research.2020; 51(5): 419. CrossRef
Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy
Xiujuan Xu, Zhongming Wang, Shunian Jiang, Yuping Shang, Yan Wu
Radiation Oncology.2019;[Epub] CrossRef
Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma
Ying Yang, Jun Jia, Zhiwei Sun, Feng Du, Jing Yu, Chuanling Liu, Yanjie Xiao, Xiaodong Zhang, Qingyi Wei
PLOS ONE.2017; 12(8): e0182660. CrossRef
The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy
Hyun-Jeong Shim, Min-Ho Shin, Hee-Nam Kim, Jo-Heon Kim, Jun-Eul Hwang, Woo-Kyun Bae, Ik-Joo Chung, Sang-Hee Cho
Cancer Research and Treatment.2016; 48(1): 71. CrossRef
Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
Yong-Hyub Kim, Sang-Yun Song, Hyun-Jeong Shim, Woong-Ki Chung, Sung-Ja Ahn, Mee Sun Yoon, Jae-Uk Jeong, Ju-Young Song, Taek-Keun Nam
Radiation Oncology Journal.2015; 33(1): 12. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer
Eun Jin Yoo, Jun Chul Park, Eun Hye Kim, Chan Hyuk Park, Choong Nam Shim, Hyun Jik Lee, Hyun Soo Chung, Hyuk Lee, Sung Kwan Shin, Sang Kil Lee, Chang Geol Lee, Yong Chan Lee
Digestive and Liver Disease.2014; 46(9): 846. CrossRef

12,611 View
92 Download
19 Crossref

Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma: Joon Suk Park, Joon Young Choi, Seung Hwan Moon, Yong Chan Ahn, Jeeyun Lee, Dohun Kim, Kwhanmien Kim, Young Mog Shim; Cancer Res Treat. 2013;45(1):22-30. Published online March 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.1.22

Abstract PDF PubReader ePub

PURPOSE
Parameters of positron emission tomography-computed tomography (PET-CT) were compared with the results of histopathologic examination in order to determine which can provide an objective indication of response after neoadjuvant chemoradiation for treatment of thoracic esophageal squamous cell carcinoma (SCC).
MATERIALS AND METHODS
Between August 2003 and January 2010, data on 25 patients who underwent neoadjuvant chemoradiation and subsequent resection for treatment of esophageal SCC were retrospectively reviewed. Changes in maximum standardized uptake value (DeltaSUVmax), metabolic tumor volume (DeltaMTV), and total lesion glycolysis (DeltaTLG) were analyzed by comparison with the histopathologic findings.
RESULTS
Pathologic complete remission (CR) for the main tumor was achieved in 11 patients. Postradiation esophagitis was observed in 10 patients. DeltaSUVmax of the main tumor was significantly greater in the CR group than in the partial response (PR) group (p=0.039), while DeltaMTV and DeltaTLG of the main tumor were not (p=0.141 and p=0.349, respectively). The cut-off DeltaSUVmax value for CR was estimated as 72.1%, indicating significantly better accuracy than visual interpretation (p=0.045). Of the 48 involved lymph nodes, DeltaSUVmax and DeltaMTV of lymph nodes were significantly greater in the CR group than in the PR group (p=0.045 and p=0.014, respectively), while DeltaTLG was not (p=0.063). The cut-off value of DeltaSUVmax for prediction of CR in lymph nodes was calculated as 50.67%.
CONCLUSION
PET-CT could be used for prediction of response to neoadjuvant treatment in thoracic esophageal SCC. DeltaSUVmax may be a more significant predictor for CR after neoadjuvant chemoradiation than DeltaTLG and DeltaMTV.

Citations

Citations to this article as recorded by

PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy
Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Kohei Kemuriyama, Yoshihiro Sasaki, Kazuhiro Imai, Eri Maeda, Yoshihiro Minamiya
Annals of Surgical Oncology.2022; 29(2): 1336. CrossRef
Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
Wei-Hsiang Feng, Ying-Yi Chen, Yen‐Shou Kuo, Kuan-Hsun Lin, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang
BMC Cancer.2022;[Epub] CrossRef
SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Yoshihiro Sasaki, Kazuhiro Imai, Yoshihiro Minamiya
World Journal of Surgical Oncology.2021;[Epub] CrossRef
18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy
Seokmo Lee, Yunseon Choi, Geumju Park, Sunmi Jo, Sun Seong Lee, Jisun Park, Hye-Kyung Shim
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef
Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Ben M. Eyck, Barbera D. Onstenk, Bo J. Noordman, Daan Nieboer, Manon C. W. Spaander, Roelf Valkema, Sjoerd M. Lagarde, Bas P. L. Wijnhoven, J. Jan B. van Lanschot
Annals of Surgery.2020; 271(2): 245. CrossRef
Utility of positron emission–computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation
Jiyun Lee, Joon Young Choi, Sung Won Lim, Myung-Ju Ahn, Keunchil Park, Jae Il Zo, Young Mog Shim, Dongryul Oh, Jong-Mu Sun
European Journal of Cardio-Thoracic Surgery.2020; 58(5): 1019. CrossRef
Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis
Didi J.J.M. de Gouw, Bastiaan R. Klarenbeek, Mitchell Driessen, Stefan A.W. Bouwense, Frans van Workum, Jurgen J. Fütterer, Maroeska M. Rovers, Richard P.G. ten Broek, Camiel Rosman
Journal of Thoracic Oncology.2019; 14(7): 1156. CrossRef
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
Won Kyung Cho, Dongryul Oh, Yong Chan Ahn, Young Mog Shim, Jae Ill Zo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park
Oncotarget.2017; 8(2): 3542. CrossRef
Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management
Mian Xi, Steven H. Lin
EMJ Oncology.2017; : 78. CrossRef
Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma
Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Ichiko Yamakita, Tomoaki Kurokawa, Morihito Okada
The Annals of Thoracic Surgery.2016; 102(4): 1132. CrossRef
PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma
Hui Yuan, Daniel K.H. Tong, Varut Vardhanabhuti, Simon Y.K. Law, Keith W.H. Chiu, Pek-Lan Khong
Nuclear Medicine Communications.2016; 37(9): 947. CrossRef
Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival
K. E. O’Sullivan, E. T. Hurley, J. P. Hurley
Gastroenterology Research and Practice.2015; 2015: 1. CrossRef
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
Arpit Chhabra, Leonard T Ong, Deborah Kuk, Geoffrey Ku, David Ilson, Yelena Y Janjigian, Abraham Wu, Heiko Schöder, Karyn A Goodman
British Journal of Cancer.2015; 113(12): 1658. CrossRef

12,780 View
55 Download
13 Crossref

First
Prev
Page of 1
Next
Last

Search